Abigail Brooks, MA

The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumab’s second approval in IBD, the first being ulcerative colitis in 2023.

The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.

ChatGPT effectively simplified information about more than 60 glomerular disease terms to enhance readability, but medical accuracy decreased.

Flemming describes increasing rates of AH among adolescents and young adults, with females facing the greatest increases and worse outcomes than males.

In patients with MASLD and T2D, GLP-1 RA use was linked to a 16% relative risk reduction in major adverse liver outcomes compared with SGLT2i use.

The new definition uses both age and GFR without body surface area correction to determine the threshold value for hyperfiltration.

Pediatric liver transplant centers with greater within-center variability in induction type had higher rates of 1-year rejection.

The randomized trial is the first to assess fecal microbiota transplantation for treating diabetic gastroenteropathy, highlighting its safety and efficacy.

As the number of metabolic components increased, so did the risk of adverse outcomes in patients with biopsy-proven IgAN.

Non-Hispanic Black and Hispanic children were less likely to undergo preemptive KT and had longer wait times than non-Hispanic White children.

Study findings suggest patients with MASLD face a 2.59-fold increased risk of heart failure, especially HFpEF, relative to those without MASLD.

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.

From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.

The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting

The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.

Study findings suggest outcomes observed with intensive blood pressure targets in SPRINT are transportable to patients with CKD in clinical practice.

Findings suggest the potential value of anti-gliadin and anti-F-actin IgA for risk stratification in patients with primary sclerosing cholangitis.

Systematic review findings point to bias and insufficient clinical applicability with current mortality risk models in patients with kidney failure.

The December month in review spotlights hepatic FDA news as well as the latest research in viral hepatitis and MASH.

The December month in review spotlights top GI pipeline updates, FDA news, a feature, and IBS research from the final month of 2024.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

2024 was a historic year in hepatology, characterized by notable hepatic FDA approvals, pipeline developments, new WHO HBV guidelines, and more.

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

The proposed rule seeks to establish and require standardized testing methods to detect and identify asbestos in cosmetic products with talc.

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

Patients with PSC had worse death, transplant, liver-related mortality, and liver-related decompensation outcomes than PBC and autoimmune hepatitis.

The ML model exhibited better predictive performance than previous traditional HCC models in patients with chronic HBV on long-term antiviral therapy.